Cure8 research brief
Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world cohorts complement clinical trials by showing outcomes in routine practice across diverse patients.
Adult patients with moderate-to-severe ulcerative colitis, clinicians prescribing advanced IBD therapies, and researchers studying real-world medication effectiveness.
The study is observational and uses real-world hospital data from a large cohort, so its strengths include size and generalizability in routine care settings. However, observational designs cannot prove causation; unmeasured confounding or selection factors may influence results.
Decisions about starting or switching therapies should still be made with your clinician. This study supports effectiveness for reducing hospitalizations but does not replace clinical trials, individualized risk–benefit discussions, or monitoring for safety.
This is an observational cohort (hospital-based) with outcomes reported up to 2 years and adjusted analyses; it cannot establish causality and may be subject to residual confounding. The article provides an abstract-level summary rather than randomized trial data. Safety outcomes and detailed subgroup data should be reviewed in the full paper and discussed with clinicians.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Japan Agency for Medical Research and Development, award JP26fk0210174; Japan Agency for Medical Research and Development, award JP26fk0210186; Japan Agency for Medical Research and Development, award JP26fk0310535; Japan Agency for Medical Research and Development, award JP26fk0310545; Japan Agency for Medical Research and Development, award JP26fk0210188; Japan Agency for Medical Research and Development, award JP26fk0310551; award JP26fk0210174; award JP26fk0210186; award JP26fk0310535; award JP26fk0310545; award JP26fk0210188; award JP26fk0310551; Japanese Ministry of Health, Labour and Welfare, award 26HC2003; Japanese Ministry of Health, Labour and Welfare, award 26HC2002; Japanese Ministry of Health, Labour and Welfare, award 26HC2001
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
